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Abstract
Background: Cancer pain is a devastating condition. Pain in the orofacial region, may be present as the single 
symptom of cancer or as a symptom of cancer in its later stages. This manuscript revises in a comprehensive man-
ner the content of the conference entitled “Orofacial Pain and Cancer” (Dolor Orofacial y Cancer) given at the VI 
Simposio International “Advances in Oral Cancer” on the 22 July, 2016 in Donostia.
Material and Methods: We have reviewed (pubmed-medline) from the most relevant literature including reviews, 
systematic reviews and clinical cases, the significant and evidence-based mechanisms and mediators of cancer-
associated facial pain, the diverse types of cancers that can be present in the craniofacial region locally or from 
distant sites that can refer to the orofacial region, cancer therapy that may induce pain in the orofacial region as 
well as discussed some of the new advancements in cancer pain therapy. 
Results: There is still a lack of understanding of cancer pain pathophysiology since depends of the intrinsic hetero-
geneity, type and anatomic location that the cancer may present, making  more challenging the creation of better 
therapeutic options. Orofacial pain can arise from regional or distant tumor effects or as a consequence of cancer 
therapy. 
Conclusions: The clinician needs to be aware that the pain may present the characteristics of any other orofacial 
pain disorder so a careful differential diagnosis needs to be given. Cancer pain diagnosis is made by exclusion and 
only can be reached after a thorough medical history, and all the common etiologies have been carefully investi-
gated and ruled out. The current management tools are not optimal but there is hope for new, safer and effective 
therapies coming in the next years.
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Introduction
Pain due to cancer is a devastating consequence for 
many patients worldwide. Pain is defined as an unpleas-
ant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms 
of such a damage as described by the International As-
sociation for the Study of Pain. Pain, IASP Pain Ter-
minology, 1994. The pain experience is fundamentally 
protective and this quality can be illustrated when it is 
the first symptom of cancer. However, the pain experi-
ence can become maladaptive in response to damage or 
in the absence of an imminent damage, and as a result, 
not achieving its role as a protective mechanism. 
Orofacial pain can arise as a symptom of regional or 
distant cancers resulting from nociceptive/somatic, 
neuropathic, inflammatory and visceral mechanisms 
(1-3). It is important to underscore that the characteris-
tics of the pain can imitate the symptomatology of any 
orofacial pain disorder with descriptors of dull, aching, 
sharp, shooting, stabbing, burning, pulling, and throb-
bing pain, and refer pain to any craniofacial structure 
regionally or from a distant site (3). Therefore, the cli-
nician needs to be aware of the diverse orofacial pain 
disorders and to understand that cancer pain must be 
included in the differential diagnosis of patients with 
unexplained and intractable orofacial pain.
Key players in oral cancer pain
The pathophysiology of cancer pain is very complex. 
Unfortunately, there is still a lack of understanding of 
the mechanisms of cancer pain that has prevented the 
advancement of new targeted therapies due to the dif-
ferent etiologies of the diverse types of cancers, the 
tumor microenvironment and the anatomic location of 
the cancer per se (4).  Pain may be the consequence of 
a primary, systemic or metastatic cancer and may re-
flect changes in both peripheral and central nervous 
systems.
Different mechanisms are involved in the pathophysiol-
ogy of cancer pain (3,4). Cancer cells have the ability 
to infiltrate nerves along the epineural, perineural and 
endoneural space, inducing tissue infiltration and nerve 
damage, and this is known as perineural invasion (PNI) 
(5,6) and is associated with tumor progression and lo-
cal recurrence (6,7). Not all cancers lead to PNI, but it 
is reported in up to 80% of head and neck cancer pa-
tients, the most affected nerves are the trigeminal and 
the facial nerve (8). PNI is present in squamous cell 
carcinoma, adenoid cystic carcinoma, lymphoma, and 
rhabdomyosarcoma (8,9).  
Oral cancers are able to secrete mediators in the sur-
rounding microenvironment in an autocrine and para-
crine manner supporting cancer proliferation and me-
tastasis (10,11). These mediators have a nociceptive 
quality and are able to directly excite and sensitize pri-
mary afferent neurons innervating the cancer microen-
vironment (12). Cancer-derived nociceptive mediators 
include inflammatory cytokines such as TNF-ɑ and 
other interleukins, neurotrophic factors, ATP, protons, 
proteases, and endothelins (12-14). 
Approximately 90% of the head and neck cancers are 
squamous cell carcinomas (SCC) (15). Oral squamous 
cell carcinoma (OSCC) is commonly localized in the 
tongue (16), is severely painful and spontaneous facial 
pain has been reported as a primary symptom (15-17). 
Endothelin-1 (ET-1) has nociceptive effects in the tumor 
microenvironment and it is highly secreted in OSCC and 
targeting ET-1 in pre-clinical models has shown to have 
anti-nociceptive effects (18-20). In addition, OSCC also 
produces nerve growth factor (NGF) which has nocic-
eptive properties. In pre-clinical models, targeting NGF 
has been shown to relieve cancer pain, cachexia and 
progression (14). High levels of ATP have been shown in 
human head and neck SCC (HNSCC) tissue. The tumor 
microenvironment of  HNSCC is heavily innervated by 
nerve fibers expressing both P2X2 and P2X3 receptors 
that may have target potential, since ATP causes their 
activation and NGF induces their hypersensitivity at 
the level of the trigeminal ganglion (13). Chronic can-
cer pain is associated with elevated serine proteases in 
the tumor microenvironment and the protease-activated 
receptor 2 (PAR2) present in peripheral nerves has been 
shown to play an important role. In a transgenic model 
of PAR2-deficient mice, the development of chronic 
cancer pain was prevented (21).
 
Orofacial pain as a symptom of cancer
It is very important to recognize that cancer in the oro-
facial region not only presents spontaneous pain but 
pain with function affecting significantly the quality of 
life of the patient. The normal biomechanics of eating, 
drinking, swallowing and talking could be compro-
mised and be painful.  
- Head and neck cancers
The onset of orofacial pain that is exacerbated during 
normal oral function is a key predictor for the transition 
from oral precancer to cancer (22). Regional orofacial 
pain and other sensory disturbances occur in 80% of 
patients with head and neck cancers (23). It is important 
to note that perineural spread of head and neck tumors 
can give symptomatology of trigeminal neuropathic 
pain, with sensation of burning, tingling, achy feelings 
as well as neuralgic symptoms such as sharp shooting 
electrical pains, and be triggered by function and even 
to present symptomatology of neurovascular disorders 
such as headache (9,24). A critical step is that a care-
ful examination should be considered since the pain can 
be reported in any structure of the craniofacial region 
such as a toothache, pain in the gingiva, tongue, face, 
neck, ear and palate (17). The pain can be referred to 
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the temporomandibular joint (TMJ) and be described as 
dull aching pain and present all the signs and symptoms 
of temporomandibular disorders (TMD), and therefore 
it could be misdiagnosed (25,26). Furthermore, intrac-
ranial tumors may present headache and orofacial pain 
symptoms such as trigeminal or glossopharyngeal neu-
ralgia, so neuroimaging must be considered to confirm 
the diagnosis (27). It is important to recognize that 
symptoms of  TMD, trigeminal neuralgia and persistent 
idiopathic facial pain are the three most common pain 
presentations in patients with intracranial tumors that 
come to the dental office (28).
- Metastasis
It has been reported in a retrospective study that of 114 
cases of metastatic tumors in the jaws, in 60% of these 
cases the lesion was the only indication of a primary 
malignancy elsewhere (29). Malignancies originating 
from thyroid, esophagus, breast, lung, kidney, liver, fe-
male reproductive system, prostate, colon and rectum 
can metastasize to the orofacial region (30-32). Bone 
metastases such as in the mandible present persistent 
pain, swelling and other sensory disturbances (30,33). 
It is very important to consider that symptomatology 
resembling trigeminal neuralgia has been reported as a 
symptom of prostate cancer when the metastatic lesion 
involved the mandible (34), and in breast cancer when it 
involved the pterygopalatine fossa (35). Lung and breast 
malignancies can metastasize to the TMJ, and TMJ pain 
may be the first symptom of metastasis (36). 
- Non-metastatic tumors
Orofacial pain referred from non-metastatic cancer is 
very rare but it has been reported that lung cancer and 
mediastinal malignant disease secondary to lung can-
cer can refer orofacial pain in the ipsilateral side (37, 
38). This referred pain could be provoked by compres-
sion of the vagus nerve by the lung (or any other organ 
or structure along the nerve), causing a convergence of 
somatic and visceral afferent inputs to the trigeminal 
nucleus caudalis, causing pain symptomatology in these 
regions (39). The pain has been described as intractable, 
unexplained, debilitating, severe, aching and paroxys-
mal, and with a poor response to therapy (37,38,40,41). 
Furthermore, neuralgic symptoms such as trigeminal 
neuralgia have been reported as the only symptom of 
pancreatic cancer (42).
- Systemic Cancer
Lymphoma, leukemia and myeloma are common neo-
plasias and they can be painful when they infiltrate 
bone, gingiva and when in close proximity to teeth (43-
46). The osteolytic lesions present in multiple myeloma 
can induce odontogenic and bone pain, swelling of the 
area, root resorption, and tooth mobility, therefore, 
careful consideration needs to be given to rule out an 
odontogenic cause or systemic disease (46). These sys-
temic cancers, in addition to pain, are associated with 
other neurosensory symptoms, such as the numb chin 
syndrome (NCS), which is a neuropathy described by 
numbness and hypoesthesia in the mental nerve distri-
bution (47) and can present neuroleukemiosis (48,49). 
- Paraneoplastic Syndrome
This phenomena can be present in response to breast 
cancer, gynecologic tumors, small cell lung cancer and 
hematologic malignancies (50). Paraneoplastic neuropa-
thies or paraneoplastic syndrome refers to signs and 
symptoms similar to an autoimmune response that at-
tacks the nervous system as a result of the presence of 
cancer, but not as a result of the local mass (3). These 
types of neuropathies are rare in the orofacial region 
(51), but trigeminal pain with a history of diarrhea and 
astenia has been reported in response to small cell lung 
carcinoma (52).
 
The paradox of cancer treatment 
New scientific paradigms and protocols are being im-
plemented for cancer therapies that have extended the 
life of the cancer patient with new advancements in 
chemotherapy and radiotherapy. However, these im-
munotherapeutic approaches to restore the survival and 
function of the immune effectors, in addition to tumor 
specific targets to eradicate cancer without causing 
damage to healthy organs and tissue, remain a challenge 
(53-55). Therefore, the paradox rests in that extending 
the life of the cancer patient may extend the duration of 
experiencing pain and therefore, living with a quality of 
life less than optimal. 
Pain as a consequence of cancer therapy is a very unfor-
tunate problem. In a systematic review from 52 studies, 
59% of cancer patients presented pain with anticancer 
treatment, 33% after cancer treatment, and more than 
one third of cancer patients reported their pain as mod-
erate to severe (56). Chemotherapy can produce severe 
peripheral neurotoxicity leading to neuropathic pain 
(57). Orofacial pain of neuropathic origin can arise as 
a consequence of surgery (tumor resection), chemother-
apy, and radiotherapy, or combination therapy (1,58). 
Most of the patients undergoing chemotherapy and ra-
diotherapy for head and neck cancers develop oral mu-
cositis which is extremely painful (59,60). The quality 
of life for these patients gets severely diminished since 
for some of them it is too painful to eat, so an adequate 
nutrition is compromised. In addition, xerostomia can 
be present making them more susceptible to rampant 
caries and also they are more susceptible to candidiasis 
and herpetic infections (59,61,62). 
The current management of orofacial pain in cancer 
pain patients is similar to cancer pain in other parts of 
the body (51). Management involves anticonvulsants, 
antidepressants, NMDA antagonists, opioids, cannabi-
noids, topical agents and local anesthetics (63). For oral 
mucositis, management also includes mouthwashes with 
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antimicrobial, analgesic, anesthetic and anti-inflamma-
tory properties, as well as oral mucosal protectants, to 
create a protective shield against irritation (59,61). The 
WHO analgesic ladder has shown these approaches to 
be successful in achieving adequate pain control in 80-
90% of patients, but there is not enough data about the 
control of orofacial pain independent of oral mucositis 
(non-mucositis pain) (64). Medications such as opioid 
regimens may reduce the pain for some patients but the 
development of tolerance and side effects are challeng-
ing for patients when larger dosages need to be adminis-
tered. Therefore, new treatment approaches that manage 
the pain without sacrificing the cancer targeted therapy 
are urgently needed. 
Moreover, musculoskeletal complaints can arise after 
head and neck surgery and radiation. Myofascial pain 
can be present as trismus, contracture, fibrosis and scar-
ring of the muscles of mastication and TMJ ligaments 
(61,65-67) compromising daily life activities such as eat-
ing because they can cause severe limitations of mouth 
opening. Therefore, it is recommended that the patient 
begins a physical therapy protocol before and after the 
procedure to maintain an optimal mouth opening.
    
New treatments, new hopes
Chemotherapy induced peripheral neuropathy (CIPN) 
and chronic neuropathic pains including burning oral dys-
esthesia as well as oral mucositis, are major side effects 
that warrant dose reduction of the antitumor agent and 
therefore affecting greatly the cancer prognosis (68,69). 
An ideal anti-tumor treatment should offer no painful 
side effects without sacrificing effective anti-tumor ef-
fects overall stabilizing the quality of life of the patient in 
their pathway to health. New understanding in CIPN may 
provide the foundation for effective treatments and offer 
new hopes in the battle against cancer pain. 
Paclitaxel is an effective and widely used chemothera-
peutic indicated for treating non-small cell lung carci-
nomas, Kaposi’s sarcoma, breast and ovarian cancer 
and head and neck cancer (70,71). 
Peroxynitrite (PN) is a powerful pro-nociceptive and 
nitroxidative species that has been shown in the induc-
tion and the maintenance of persistent pathophysiologi-
cal pain (72,73). It has been reported that PN production 
in response to activation of nitric oxide synthases and 
NADPH oxidase in the spinal cord contributes to the 
neuropathological changes involved in paclitaxel in-
duced CIPN. In a preclinical model of CIPN induced by 
paclitaxel, was demonstrated that targeting PN can not 
only reverse but prevent the formation of CIPN without 
jeopardizing the anti-tumor effects of paclitaxel (71). 
Therefore the development of PN-targeted therapeutics 
may offer a new avenue for 
management. Moreover, pre-clinical studies have shown 
that A3 adenosine receptor (A3AR) agonists have antino-
ciceptive effects (74-77). It has been demonstrated that 
activation of the A3AR with selective A3AR agonists 
blocked the development of CINP induced by different 
chemotherapeutics, without interfering with antican-
cer effects by inhibiting key pathways known to drive 
central sensitization (74,76-79). Treatment with C1-IB-
MECA an A3A agonist reduced tumor growth as well as 
bone related pain as shown in rodent models of breast 
cancer bone metastasis (77,80). Moreover, MRS55698 
a newer generation and highly selective A3AR agonist 
has shown to be effective in chronic pain states (81). 
In regards to human studies, it has been shown that in 
trials for inflammatory conditions including glaucoma, 
hepatitis, psoriasis and rheumatoid arthritis, A3A ago-
nists offer tolerability and a good therapeutic index sup-
porting an exciting avenue for their use in the manage-
ment of chronic pain (82). Recently, a I/II clinical trial 
by Can-Fite BioPharma showed that C1-IB-MECA is 
successful as an anti-tumorigenic against hepatocecel-
lular carcinoma (75), so the use of these agonists may 
offer a dual effect treating the cancer as well as the pain 
in cancer. 
A great promise in regards this new target is that the 
effect of these A3AR agonists is independent of endo-
cannabinoids or opioid pathways to exert their anti-
nociceptive function as shown in pre-clinical models 
(77). A3AR  are not subjected to analgesic tolerance and 
do not create reward (77).  Therefore, the use of A3AR 
agonists may be a novel avenue that will offer to the 
cancer patient a safer, more tolerable, anti-cancer drug 
with anti-nociceptive properties without the risk of tol-
erance or abuse. 
Conclusions
Cancer pain is a devastating consequence of the cancer 
itself and unfortunately a sequela of cancer treatment. 
Cancer pain patients need a compassionate, multidisci-
plinary team for their management. The quality of life 
in head and neck cancer patients decreases dramatically 
since because of the pain they present challenges in ea-
ting, talking swallowing and breathing and sometimes 
because of the same pain a dose reduction of the can-
cer therapy is needed, affecting in this way their cancer 
prognosis of survival. Preventive modalities should be 
implemented when orofacial pain is present as a result 
of cancer therapy therefore, in the cases of radiation or 
surgical procedure, a physical therapy protocol before 
and after the procedures is imperative to maintain a 
functional mouth opening.  There is still a lot to under-
stand in regards cancer pain but new advancements in 
potential targets are on the horizon that promise to be 
potentially beneficial. As clinicians we need to be aware 
that tumor size generally is not relevant in correlation 
with pain severity. In addition, cancer related pain in 
the orofacial region can be a symptom of a local tumor 
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or a distant tumor and can present the same characteris-
tics of the different orofacial pain disorders, mimicking 
these disorders, such as TMD or trigeminal neuralgia or 
neuropathic pain.  Since sometimes pain can be the sin-
gle symptom of cancer and in some cases it can be the 
first symptom of cancer, or a symptom of later stages, 
it needs to be underscored that pain itself should not be 
used as the only diagnostic criteria for cancer. Cancer 
pain diagnosis is made by exclusion and only can be 
reached after a thorough medical history, and all the 
common etiologies have been carefully investigated and 
ruled out (3). When in doubt, always seek the referral to 
an orofacial pain specialist for further evaluation.
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